JP7805170B2 - 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 - Google Patents

前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Info

Publication number
JP7805170B2
JP7805170B2 JP2021578240A JP2021578240A JP7805170B2 JP 7805170 B2 JP7805170 B2 JP 7805170B2 JP 2021578240 A JP2021578240 A JP 2021578240A JP 2021578240 A JP2021578240 A JP 2021578240A JP 7805170 B2 JP7805170 B2 JP 7805170B2
Authority
JP
Japan
Prior art keywords
compound
formula
psma
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021578240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538478A (ja
Inventor
エフ． マリアニ，マウリツィオ
フガッツァ，ロレンツァ
キッコ，ダニエラ
ギルバート ポンパー，マーティン
レイ，サンギータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2022538478A publication Critical patent/JP2022538478A/ja
Priority to JP2025120662A priority Critical patent/JP2025165975A/ja
Application granted granted Critical
Publication of JP7805170B2 publication Critical patent/JP7805170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021578240A 2019-07-02 2020-06-30 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 Active JP7805170B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120662A JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184015.6 2019-07-02
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120662A Division JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Publications (2)

Publication Number Publication Date
JP2022538478A JP2022538478A (ja) 2022-09-02
JP7805170B2 true JP7805170B2 (ja) 2026-01-23

Family

ID=67145647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578240A Active JP7805170B2 (ja) 2019-07-02 2020-06-30 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
JP2025120662A Pending JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120662A Pending JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Country Status (16)

Country Link
US (1) US20230226227A1 (enExample)
EP (1) EP3993837A1 (enExample)
JP (2) JP7805170B2 (enExample)
KR (1) KR20220044496A (enExample)
CN (3) CN120441497A (enExample)
AR (1) AR119331A1 (enExample)
AU (3) AU2020299974A1 (enExample)
BR (1) BR112021026812A2 (enExample)
CA (1) CA3144557A1 (enExample)
CL (1) CL2021003525A1 (enExample)
CO (1) CO2021017708A2 (enExample)
IL (1) IL289039A (enExample)
MX (1) MX2022000136A (enExample)
PH (1) PH12021553284A1 (enExample)
TW (1) TW202114742A (enExample)
WO (1) WO2021001360A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219719A1 (en) * 2020-04-29 2021-11-04 Advanced Accelerator Applications (Italy) Srl Methods for radiolabelling psma binding ligands and their kits
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222778A1 (en) 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
HUE045028T2 (hu) * 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
GEP20237479B (en) * 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR20250057132A (ko) 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
IL276528B2 (en) * 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222778A1 (en) 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Also Published As

Publication number Publication date
PH12021553284A1 (en) 2022-08-01
JP2025165975A (ja) 2025-11-05
CO2021017708A2 (es) 2022-05-20
BR112021026812A2 (pt) 2022-02-22
CN120441497A (zh) 2025-08-08
WO2021001360A1 (en) 2021-01-07
EP3993837A1 (en) 2022-05-11
JP2022538478A (ja) 2022-09-02
MX2022000136A (es) 2022-04-27
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
TW202114742A (zh) 2021-04-16
US20230226227A1 (en) 2023-07-20
AU2024200850A1 (en) 2024-02-29
CN114341118A (zh) 2022-04-12
AU2024200850B2 (en) 2025-09-04
IL289039A (en) 2022-02-01
CN120441498A (zh) 2025-08-08
KR20220044496A (ko) 2022-04-08
AU2025271182A1 (en) 2025-12-18
CA3144557A1 (en) 2021-01-07
CL2021003525A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP6556805B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
CN111285918B (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
JP2022518956A (ja) がん診断用画像化剤
IL194826A (en) Compounds 4n are conjugated to a target ligand and a kit containing it
JP2022513630A (ja) 治療および画像化のためのデンドリマー
JP7608378B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト
HK1123306B (en) Compositions and methods for cellular imaging and therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260113

R150 Certificate of patent or registration of utility model

Ref document number: 7805170

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150